Focus: Neurelis is a small-stage biotech focused on licensing, developing, and commercializing neurology and psychiatry product candidates from its San Diego headquarters. The company operates at micro-cap scale with 1–50 employees and derives 100% of revenue from its marketed product VALTOCO (diazepam nasal spray).
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Stable — net +2 jobs in 30d
3 added, 1 removed. Backfill posture.
Neurelis suits risk-tolerant early-career or mid-career professionals seeking hands-on impact in a seizure-focused biotech, but only if you can tolerate near-complete product-line risk and minimal organizational scale.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole revenue driver (100% of top line); nasal spray formulation of benzodiazepine with 16-year exclusivity runway provides commercial foundation for company operations.
Help build intelligence for Neurelis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Neurelis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Better Late Than Never? FDA Receives Long-Awaited Statutory Fix for Orphan Drug Exclusivity in Recent Appropriations Act - JD Supra
Better Late Than Never? FDA Receives Long-Awaited Statutory Fix for Orphan Drug Exclusivity in Recent Appropriations Act JD Supra
8-K Filing: Aquestive Therapeutics, Inc. (AQST) (CIK 0001398733) — EX-99.1
EX-99.1
Congress Enacts Long-Awaited Fix to Orphan Drug Exclusivity in 2026 Consolidated Appropriations Act - Spencer Fane
Congress Enacts Long-Awaited Fix to Orphan Drug Exclusivity in 2026 Consolidated Appropriations Act Spencer Fane
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Increased interval between seizure clusters across time in pediatric patients treated with the immediate-use seizure medication diazepam nasal spray.
A triple burden in native Hawaiian and Pacific Islander patients with epilepsy: The cardiometabolic risks of obesity, diabetes, smoking, and their association with seizure control.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo